SLS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.063

-20.84%

-0.067

-4.76%

-0.067

-4.76%

Estimates Revision

The market is revising No Change the revenue expectations for SELLAS Life Sciences Group, Inc. (SLS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 81.15%.

EPS Estimates for FY2025

Revise Downward

-10.34%

In Past 3 Month

Stock Price

Go Up

+81.15%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast SLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLS is 7.25 USD with a low forecast of 7.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

7.00

Averages

7.25

High

7.50

Current: 0.000

Low

7.00

Averages

7.25

High

7.50

Maxim

Buy

maintain

$4 -> $7

2025-07-16

Reason

Maxim

Price Target

$4 -> $7

2025-07-16

maintain

Buy

Reason

Maxim raised the firm's price target on Sellas Life Sciences to $7 from $4 and keeps a Buy rating on the shares. Shares have risen about 90% year-to-date as the company continues to execute across its Acute Myeloid Leukemia, or AML, programs, the analyst tells investors in a research note. Maxim further cites the company's galinpepimut-S in Phase 3 and yesterday's positive SLS009 data hitting all its endpoints, adding that its higher price target factors in SLS009 in first-line AML as a potential triplet combination with venetoclax/azacitidine.

Valuation Metrics

The current forward P/E ratio for Sellas Life Sciences Group Inc (SLS.O) is -16.11, compared to its 5-year average forward P/E of -3.52. For a more detailed relative valuation and DCF analysis to assess Sellas Life Sciences Group Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.52

Current PE

-16.11

Overvalued PE

-1.34

Undervalued PE

-5.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.09

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.33

Undervalued EV/EBITDA

-0.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.54

Current PS

0.00

Overvalued PS

32.89

Undervalued PS

-11.80

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 581.12% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 581.12% over the last month.

Sold

Bought

SLS News & Events

Events Timeline

No data

News

3.5

01-08Globenewswire

Oncolytics Biotech Fortifies IP Protection, Extends Pelareorep Commercial Runway to 2044

8.5

01-02Benzinga

Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%

7.0

01-02Benzinga

Ironwood Pharmaceuticals Issues FY26 Guidance, Shares Surge 57.7%

People Also Watch

Frequently Asked Questions

What is Sellas Life Sciences Group Inc (SLS) stock price today?

The current price of SLS is 3.46 USD — it has decreased -10.36 % in the last trading day.

What is Sellas Life Sciences Group Inc (SLS)'s business?

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

What is the price predicton of SLS Stock?

What is Sellas Life Sciences Group Inc (SLS)'s revenue for the last quarter?

Sellas Life Sciences Group Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Sellas Life Sciences Group Inc (SLS)'s earnings per share (EPS) for the last quarter?

Sellas Life Sciences Group Inc. EPS for the last quarter amounts to -0.06 USD, decreased -40.00 % YoY.

What changes have occurred in the market's expectations for Sellas Life Sciences Group Inc (SLS)'s fundamentals?

How many employees does Sellas Life Sciences Group Inc (SLS). have?

Sellas Life Sciences Group Inc (SLS) has 15 emplpoyees as of January 10 2026.

What is Sellas Life Sciences Group Inc (SLS) market cap?

Today SLS has the market capitalization of 589.18M USD.